"Nicotinic Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
| Descriptor ID |
D018722
|
| MeSH Number(s) |
D27.505.519.625.120.140.700 D27.505.696.577.120.140.700
|
| Concept/Terms |
Nicotinic Agonists- Nicotinic Agonists
- Agonists, Nicotinic
- Cholinergic Agonists, Nicotinic
- Agonists, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonists
- Nicotinic Agonist
- Agonist, Nicotinic
- Cholinergic Agonist, Nicotinic
- Agonist, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonist
|
Below are MeSH descriptors whose meaning is more general than "Nicotinic Agonists".
Below are MeSH descriptors whose meaning is more specific than "Nicotinic Agonists".
This graph shows the total number of publications written about "Nicotinic Agonists" by people in this website by year, and whether "Nicotinic Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 0 | 4 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nicotinic Agonists" by people in Profiles.
-
Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. JAMA. 2024 05 28; 331(20):1722-1731.
-
Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Sci Rep. 2024 03 16; 14(1):6385.
-
Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice. Nat Commun. 2024 Jan 18; 15(1):601.
-
Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021 08 29; 23(10):1682-1690.
-
Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther. 2020 12; 108(6):1315-1325.
-
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline. Alcohol Clin Exp Res. 2020 07; 44(7):1431-1443.
-
Nicotine instigates podocyte injury via NLRP3 inflammasomes activation. Aging (Albany NY). 2019 12 13; 11(24):12810-12821.
-
Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. Addiction. 2019 10; 114(10):1824-1833.
-
A Pilot Study of E-Cigarette Na?ve Cigarette Smokers and the Effects on Craving After Acute Exposure to E-Cigarettes in the Laboratory. Am J Addict. 2019 09; 28(5):361-366.
-
Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. J Pharmacol Exp Ther. 2019 02; 368(2):169-178.